|
gptkbp:instanceOf
|
gptkb:receptor_tyrosine_kinase
gptkb:drug
|
|
gptkbp:administeredBy
|
oral
|
|
gptkbp:approvalYear
|
2001
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
L01XE01
|
|
gptkbp:bioavailability
|
98%
|
|
gptkbp:brand
|
gptkb:Gleevec
gptkb:Glivec
|
|
gptkbp:CASNumber
|
152459-95-5
|
|
gptkbp:category
|
protease inhibitor
antineoplastic agent
orphan drug
|
|
gptkbp:chemicalFormula
|
C29H31N7O
|
|
gptkbp:developedBy
|
gptkb:Novartis
|
|
gptkbp:discoveredBy
|
gptkb:Brian_Druker
gptkb:Nicholas_Lydon
|
|
gptkbp:eliminationHalfLife
|
18 hours
|
|
gptkbp:excretion
|
urine
feces
|
|
gptkbp:firstBook
|
yes
|
|
gptkbp:genericAvailable
|
yes
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
imatinib (Gleevec)
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
inhibits BCR-ABL tyrosine kinase
inhibits PDGFR
inhibits c-KIT
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:molecularWeight
|
493.6 g/mol
|
|
gptkbp:patentExpired
|
yes
|
|
gptkbp:pregnancyCategory
|
D (US)
|
|
gptkbp:proteinBinding
|
95%
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
nausea
edema
fatigue
rash
muscle cramps
|
|
gptkbp:target
|
gptkb:BCR-ABL
gptkb:PDGFR
gptkb:c-KIT
|
|
gptkbp:usedFor
|
gptkb:gastrointestinal_stromal_tumor
gptkb:chronic_myeloid_leukemia
gptkb:systemic_mastocytosis
gptkb:dermatofibrosarcoma_protuberans
leukemia
hypereosinophilic syndrome
|
|
gptkbp:WHOModelListOfEssentialMedicines
|
yes
|
|
gptkbp:bfsParent
|
gptkb:Nicholas_Lydon
|
|
gptkbp:bfsLayer
|
5
|